Solubility and Stability


* Please be kindly noted that our services and products can only be used for research to organizations or companies and not intended for any clinical or individuals.

As a recognized leader in the field of drug discovery and development, coupled with more than a decade of experience, BOC Sciences is committed to the development of PROTAC®, we provide our customers with a comprehensive range of high-quality small molecule solubility and chemical stability services.


Chimera-targeted protein degradant (PROTAC) is a new therapy. Compared with macromolecular drugs such as antibodies or oligonucleotides, it retains its ability to directly act on intracellular or cell membrane target proteins. At the same time, it also has the advantages of high oral bioavailability and low manufacturing cost of small molecular drugs. But a formidable challenge to prevent PROTAC from realizing its therapeutic potential is its lack of pharmacological characteristics associated with oral drugs, that is, the "five rules" (Ro5) of Lipinski. The oral dose of the drug needs to have the characteristics of allowing dissolution and stability in the stomach, as well as from intestinal absorption and stability to the first metabolism to reach systemic circulation. Therefore, water solubility and stability are the two main physical and chemical properties that need to be optimized in the development of PROTAC drugs.

Our Services

Our Advantages


  1. Churcher, I. (2018). Protac-induced protein degradation in drug discovery: breaking the rules or just making new ones?. Journal of medicinal chemistry, 61(2), 444-452.
  2. Paiva, S. L., & Crews, C. M. (2019). Targeted protein degradation: elements of Protac design. Current opinion in chemical biology, 50, 111-119.

* PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.

Our Products

Online Inquiry

  • Verification code




Interested in our Service & Products?
Need detailed information?